Company intelligence / Profile preview

Viron Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

Viron Therapeutics is a clinical-stage biopharmaceutical company that develops viral proteins to treat and prevent human inflammatory disorders. Several of their programs appear to have been discontinued, including VT-384, Laromustine, VT-111, and VT-346.

Therapeutic areas: GastroenterologyCardiovascularRheumatologyImmunologyHematology
Modalities: Viral proteins
Industry: Biotech

Drug pipeline

2 assets

serp-1

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Viron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viron Therapeutics.

Explore the full profile